Philipp Gödel

Feb 5, 2024 | onlinelibrary.wiley.com | Nadine Kutsch |Philipp Gödel |Conrad-Amadeus Voltin |Michael Hallek

What is the new aspect of your work? Data on patients treated with CAR T-cells for DLBCL-RT are limited in patient numbers and follow-up. To our knowledge, this is our first report of a long-term response of up to 4 years in a patient with DLBCL-RT treated with tisagenlecleucel after aHSCT. What is the central finding of your work? CAR T-cell therapy was feasible in a patient with DLBCL-RT treated with tisagenlecleucel after aHSCT. Grade 2 CRS was manageable with tocilizumab.